BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30471851)

  • 1. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
    Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
    Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
    di Luccio E
    J Cancer Prev; 2015 Jun; 20(2):113-20. PubMed ID: 26151044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancers and the NSD family of histone lysine methyltransferases.
    Morishita M; di Luccio E
    Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High yield recombinant expression and purification of oncogenic NSD1, NSD2, and NSD3 with human influenza hemagglutinin tag.
    Shen Y; Morishita M; di Luccio E
    Protein Expr Purif; 2020 Feb; 166():105506. PubMed ID: 31563542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
    Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
    Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1.
    Morishita M; di Luccio E
    Biochem Biophys Res Commun; 2011 Aug; 412(2):214-9. PubMed ID: 21806967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NSD family of protein methyltransferases in human cancer.
    Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
    Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro.
    Allali-Hassani A; Kuznetsova E; Hajian T; Wu H; Dombrovski L; Li Y; Gräslund S; Arrowsmith CH; Schapira M; Vedadi M
    J Biomol Screen; 2014 Jul; 19(6):928-35. PubMed ID: 24595546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR backbone resonance assignment and solution secondary structure determination of human NSD1 and NSD2.
    Amin N; Nietlispach D; Qamar S; Coyle J; Chiarparin E; Williams G
    Biomol NMR Assign; 2016 Oct; 10(2):315-20. PubMed ID: 27356987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a peptide inhibitor for the histone methyltransferase WHSC1.
    Morrison MJ; Boriack-Sjodin PA; Swinger KK; Wigle TJ; Sadalge D; Kuntz KW; Scott MP; Janzen WP; Chesworth R; Duncan KW; Harvey DM; Lampe JW; Mitchell LH; Copeland RA
    PLoS One; 2018; 13(5):e0197082. PubMed ID: 29742153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
    Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
    Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives.
    Tisi D; Chiarparin E; Tamanini E; Pathuri P; Coyle JE; Hold A; Holding FP; Amin N; Martin AC; Rich SJ; Berdini V; Yon J; Acklam P; Burke R; Drouin L; Harmer JE; Jeganathan F; van Montfort RL; Newbatt Y; Tortorici M; Westlake M; Wood A; Hoelder S; Heightman TD
    ACS Chem Biol; 2016 Nov; 11(11):3093-3105. PubMed ID: 27571355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
    Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
    Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
    Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
    Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
    Bennett RL; Swaroop A; Troche C; Licht JD
    Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
    Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
    J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
    Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
    Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.